William Blair reiterated their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report report published on Thursday morning.

Several other research firms have also issued reports on SRPT. Barclays PLC initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. They issued an equal weight rating and a $46.00 price target on the stock. BidaskClub lowered shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Friday, August 4th. Robert W. Baird reaffirmed an outperform rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an outperform rating in a report on Thursday. Finally, Cowen and Company reissued an outperform rating and set a $69.00 price objective (up from $62.00) on shares of Sarepta Therapeutics in a report on Thursday, July 20th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $62.31.

Shares of Sarepta Therapeutics (SRPT) opened at 43.01 on Thursday. The firm’s 50-day moving average price is $39.34 and its 200 day moving average price is $34.16. Sarepta Therapeutics has a 52 week low of $25.47 and a 52 week high of $63.73. The stock’s market capitalization is $2.77 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the prior year, the firm posted ($1.19) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post ($1.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/11/sarepta-therapeutics-inc-srpt-stock-rating-reaffirmed-by-william-blair.html.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Douglas S. Ingram acquired 47,058 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. In the last quarter, insiders sold 78,056 shares of company stock valued at $3,224,208. Insiders own 9.60% of the company’s stock.

Several institutional investors have recently modified their holdings of SRPT. Prentiss Smith & Co. Inc. raised its position in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 3,166 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Sarepta Therapeutics in the first quarter worth about $127,000. PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,800 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares during the period. Finally, Edge Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth about $175,000. Institutional investors and hedge funds own 65.43% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.